Maxim Group analyst Jason Kolbert reiterated his Buy rating and $2.50 price target on StemCells (NASDAQ: STEM) following positive data on spine paralysis.

Kolbert notes, "The presentation included the first data on AIS B subjects to be transplanted in the Phase I/II chronic spinal cord injury trial with the HuCNS-SCcells. In contrast to AIS A patients who have no mobility or sensory perception below the point of injury, AIS B subjects are less severely injured, they are paralyzed but retain sensory perception below the point of injury." The analyst highlights that two of the three AIS B patients had significant gains in sensory perception and the third remained stable.

Kolbert notes the next catalyst is Dry Age Related Macular Degeneration. Interim results from this study will be shown at the annual meeting of the International Society for Stem Cell Research in Vancouver, Canada, from June 18-21, he notes.

For an analyst ratings summary and ratings history on StemCells click here. For more ratings news on StemCells click here.

Shares of StemCells closed at $1.39 yesterday.